Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 276-736-3 | CAS number: 72623-85-9 A complex combination of hydrocarbons obtained by treating light vacuum gas oil, heavy vacuum gas oil, and solvent deasphalted residual oil with hydrogen in the presence of a catalyst in a two stage process with dewaxing being carried out between the two stages. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C20 through C50 and produces a finished oil having a viscosity of approximately 112cSt at 40°C. It contains a relatively large proportion of saturated hydrocarbons.
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Basic toxicokinetics
Administrative data
- Endpoint:
- basic toxicokinetics in vivo
- Type of information:
- migrated information: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Study period:
- 2011
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Human study in compliance with ICH Guideline for Good Clinical Practice, 1997
Data source
Referenceopen allclose all
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 011
- Report date:
- 2011
- Reference Type:
- publication
- Title:
- Unnamed
- Year:
- 2 012
Materials and methods
- Objective of study:
- absorption
Test guideline
- Guideline:
- other: Non guideline – human testing but in compliance with ICH Guideline for Good Clinical Practice, 1997
Test material
- Reference substance name:
- 8042-47-5
- Cas Number:
- 8042-47-5
- IUPAC Name:
- 8042-47-5
- Reference substance name:
- 15 cSt Paraffinic Hydrotreated White Oil (P15H)
- IUPAC Name:
- 15 cSt Paraffinic Hydrotreated White Oil (P15H)
- Test material form:
- other: Oily liquid
- Details on test material:
- -Name of test material (as cited in study report): 15 cSt Paraffinic Hydrotreated White Oil (P15H)
-Type: Low viscosity oil
-Physical state: Liquid
- Storage condition of test material: Room temperature
- Certificate of analysis available
- Meets the purity requirements of the European Pharmacopoeia, US Pharmacopoeia, Food and Drug Administration, 21 CFR 178.3620 (a) and 21 CFR 172.878
Constituent 1
Constituent 2
Test animals
- Species:
- human
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- Age: 18-35 years of age
Body weight: 55-85 kilograms
Alcohol consumption > 2l units/week
Not pregnant or lactating, not planning to conceive during the period of the study and using acceptable contraception.
No history of medical or endocrine diseases or surgical events that may significantly affect the study outcome.
No prescribed medication (except paracetamol occasionally)
No use of specific cosmetics (e.g. body lotion, baby oils, lipstick or pomade) prior to and during study period.
Administration / exposure
- Route of administration:
- oral: capsule
- Details on exposure:
- One single oral dose of Pl5H oil was given in a gelatin capsule, followed by blood sampling at pre-determined time points up to 168 hours post administration. Capsules contained on average 71.2 mg (min 70 mg, max 74 mg) p15H -tetracosane mix
- Duration and frequency of treatment / exposure:
- Single administration
Doses / concentrations
- Remarks:
- Doses / Concentrations:
The capsules contained on average 71.2 mg (min 70 mg, max 74 mg) P15H oil - tetracosane mix. The capsules were ranked according to weight and were given to the subjects based on their body weight. The actual dosing was therefore on average 1.09 +/- 0.12 mg mix/kg BW. After correction for the 8% tetracosane present, the P15H oil dose was on average 1.00 +/- 0.11 mg/kg BW.
- No. of animals per sex per dose / concentration:
- 9
- Control animals:
- no
- Details on study design:
- One single oral dose of Pl5H oil was given in a gelatin capsule, followed by blood sampling at pre-determined time points up to 168 hours post administration. Capsules contained on average 71.2 mg (min 70 mg, max 74 mg) p15H -tetracosane mix. The study consisted of 7 days (168 h). Blood samples were taken at predose and at 1 , 2, 4, 8, 24, 48, 72, 96 and 168 h after dosing. The samples were extracted with hexane followed by analysis using two-dimensional gas chromotography-mass spectrometry (GCxGC-MS).
- Details on dosing and sampling:
- One single controlled oral dose of P15H oil was given in a capsule spiked with C24D50 (tetracosane-d50) as a marker. The intended dose P15H-oil was set at 1 mg/kg BW. Each capsule contained on average 71.2 mg mix containing 65.8 mg P15H white oil and 5.6 mg tetracosane-d50. The white mineral oil was already delivered at TNO in two glass containers at the start of the rat study in 2009. For preparing the doses for the current human volunteer study the sealed container was opened and this content was used for the preparation of the doses. The spiking of the P15H white oil and the subsequent filling of the capsules was performed by TNO in the sterile flow cupboard at Test Material Administration. The mix was prepared by mixing 0.0799 mg C24D50 in 0.9242 mg P15H oil. To avoid any potential dissolving of the gelatine capsule prior to consumption, they were filled in the early morning, about 1 h prior to consumption. The mix was prepared a few days earlier, to allow an even distribution of the intemal marker in the P15H oil. After inclusion of all subjects, the subjects received an entry number based on order of arrival on the first study day. Entry numbers consisted of the TNO study number (9051), followed by a slash ('/'), followed by a 2-digit number (01-09).
- Statistics:
- No statistical analysis was performed. For data analysis pharmacokinetic analysis was planned using WinNonlin® Version 6.1. (Phoenix).
Results and discussion
- Preliminary studies:
- No
Main ADME results
- Type:
- other:
- Results:
- The concentration of P15H in blood was below the limit of detection (0.163 ug/ml) in all samples from all subjects, hence no kinetic parameters could be derived.
Applicant's summary and conclusion
- Conclusions:
- Interpretation of results (migrated information): other: no appreciable absorption of P15H oil at a dose 2-4 fold greater than the estimated human daily intake
It was concluded that a dose of 1 mg/kg BW P15H oil in female human volunteers resulted in blood levels below the limit of detection. This suggests that there was no appreciable absorption of P15H oil at a dose that was 2-4 fold greater than the estimated human daily intake. In contrast, toxicokinetic studies conducted in Fischer 344 and Sprague- Dawley rats, showed higher bioavailability in both rat species than in humans. - Executive summary:
The absorption and kinetics of a sample of P15H white oil was investigated in nine female volunteers (age 18 -35 years) following single oral administration. The white oil was administered in a gelatine capsule, with each capsule containing on average 71.2 mg (min 70 mg, max 74 mg) P15H - tetracosane mix. After adjustment for body weight, the subjects received on average 1.09 +/- 0.12 mg mix/kg BW. After correction for the tetracosane content of the mixture (8%), the dose of P15H oil was on average 1.00 +/- 0.11 mg/kg BW. Blood samples were taken prior to treatment, and then at regular intervals over 7 days (that is: 1, 2, 4, 8, 24, 48, 72, 96 and 168 hours post-dose). The samples wereextracted with hexane followed by analysis using two-dimensional gas chromatography-mass spectrometry (GCxGC-MS). No clinical signs or adverse symptoms were reported by the volunteers. Results of blood analyses showed that the concentration of P15H white oil in the blood was below the average within laboratory detection limit (0.163 ug/mL) at all timepoints, hence no kinetic analyses were possible. At a dose 2-4 times that estimate daily intake, no appreciable absorption of P15H oil occurred.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.